Antabio: Funding, Investors & Team (Sep 2026)
Antabio is a privately-owned biopharmaceutical company that focuses on creating innovative treatments for drug-resistant infections, particularly in areas with the greatest medical needs. They specialize in developing inhibitors for bacterial metalloenzymes, which can be used alongside different antibiotics to restore their effectiveness against the most dangerous pathogens. One of their notable products is a new inhibitor for bacterial Metallo ß-lactamases ("MBLs"), which will be used in combination with a carbapenem to address a significant gap in treating drug-resistant infections. This inhibitor is intended to be safe and effective, specifically designed to combat drug-resistant nosocomial infections. In recognition of their work, Antabio was awarded the Wellcome Trust Seeding Drug Discovery Award. Established in 2009, the company is headquartered in Labege, France.
Antabio has raised $27.0M across 1 funding round on record, the most recent a Series B of $27.0M announced in Dec 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Antabio Company Profile and Key Stats
Latest funding round on record: Dec 2023.
Antabio Funding Rounds
Antabio Founders and Leadership Team
No contact details are on record for this team yet.
Antabio Funding Compared to Other Biotechnology Startups
Antabio's latest round of $27.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Antabio in Biotechnology and Labège
Companies Similar to Antabio
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Antabio Funding FAQs
What does Antabio do?
Antabio is a privately-owned biopharmaceutical company that focuses on creating innovative treatments for drug-resistant infections, particularly in areas with the greatest medical needs. They specialize in developing inhibitors for bacterial metalloenzymes, which can be used alongside different antibiotics to restore their effectiveness against the most dangerous pathogens. One of their notable products is a new inhibitor for bacterial Metallo ß-lactamases ("MBLs"), which will be used in combination with a carbapenem to address a significant gap in treating drug-resistant infections. This inhibitor is intended to be safe and effective, specifically designed to combat drug-resistant nosocomial infections. In recognition of their work, Antabio was awarded the Wellcome Trust Seeding Drug Discovery Award. Established in 2009, the company is headquartered in Labege, France.
How much funding has Antabio raised?
Antabio has raised $27.0M across 1 round on record. The most recent is a Series B of $27.0M announced in Dec 2023.
When did Antabio last raise funding?
Antabio's most recent funding round on record is a Series B of $27.0M, announced in Dec 2023.
Who is the CEO of Antabio?
Marc Lemonnier is listed as CEO at Antabio.
Where is Antabio headquartered?
Antabio is based in Labège, Midi-Pyrenees, France.
How many employees does Antabio have?
Antabio is in the 11-50 employee band.
How does Antabio's funding compare to other Biotechnology startups?
Antabio's latest round of $27.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Antabio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Antabio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.